CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 8,612	$ 4,260
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	50,319	49,541
Provision for bad debts	35,187	33,883
Gain from return of common stock	0	(5,032)
Equity in earnings of joint ventures	(8,372)	(8,129)
Distributions from joint ventures	6,785	2,929
Amortization deferred financing costs and loan discount	2,509	4,244
Loss on sale and disposal of equipment	828	375
Gain on sale of imaging centers	(3,146)	0
Stock-based compensation	5,842	4,918
Non cash severance	1,047	0
Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts receivable	(38,770)	(53,277)
Other current assets	2,981	10,420
Other assets	309	751
Deferred taxes	2,031	1,426
Deferred rent	2,137	(678)
Deferred revenue	428	60
Accounts payable, accrued expenses and other	6,857	9,039
Net cash provided by operating activities	75,584	54,730
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of imaging facilities	(22,904)	(6,603)
Investment at cost	(500)	0
Purchase of property and equipment	(52,807)	(52,110)
Proceeds from sale of imaging and medical practice assets	9,000	63
Cash distribution from new JV partner	1,473	994
Equity contributions in existing and purchase of interest in joint ventures	(80)	(1,374)
Net cash used in investing activities	(65,818)	(59,030)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on notes and leases payable	(5,297)	(9,219)
Proceeds from borrowings	170,000	476,503
Payments on Term Loan Debt	(188,396)	(463,022)
Deferred financing costs and debt discount	(5,067)	(945)
Distributions paid to noncontrolling interests	(1,065)	(492)
Proceeds from sale of noncontrolling interest, net of taxes	7,726	0
Contributions from noncontrolling partners	125	0
Proceeds from revolving credit facility	182,000	344,600
Payments on revolving credit facility	(182,000)	(343,000)
Purchase of noncontrolling interests	0	(350)
Proceeds from issuance of common stock upon exercise of options	0	150
Net cash (used in) provided by financing activities	(21,974)	4,225
EFFECT OF EXCHANGE RATE CHANGES ON CASH	38	(13)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(12,170)	(88)
CASH AND CASH EQUIVALENTS, beginning of period	20,638	446
CASH AND CASH EQUIVALENTS, end of period	8,468	358
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for interest	29,134	26,819
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Purchase of equipment and leasehold improvements	14,400	14,700
Capital lease debt related to radiology equipment	5,400	1,300
Investment in joint venture	3,000	0
Transfer of fixed assets to new joint venture	2,500	0
Transferred of assets to new majority owned subsidiary	$ 4,600	$ 0